Meningitis is a substantial contributor to mortality in children younger than 5 years of age in low- and middle-income ...

Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging ...

We’re all guilty of having our phones on the table during dinner, but it turns out this could actually be making us ill. That ...

Zai Lab and Pfizer have entered a strategic collaboration to commercialise XACDURO (sulbactam-durlobactam), a new ...

Future Microbiol. 2008;3(6):649-660.

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...

Xacduro is the only antimicrobial agent specifically developed for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB). It has been approved in the United States and in mainland China ...

Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a ...

We read every piece of feedback, and take your input very seriously.

抗生素被发现时，「细菌学之父」路易斯·巴斯德（Louis Pasteur）称之为「最大的希望」[1]。 然而，随着抗生素的广泛使用，微生物耐药问题席卷全球，「超级细菌」、「超级真菌」相继出现，成为临床医生的诊疗痛点。 2019 年，WHO 发文警告称 ...

The CTAR Programme is aimed at identifying and developing first-in-class therapeutics for infections caused by ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...